Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026

Biomarin Pharmaceutical Inc (BMRN)

A forensic read on Biomarin Pharmaceutical Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

C · Mixed — selective

Forensic grade

Safe

Financial health

12.5

Distress distance

Clean

Earnings quality

Forensic signals

45.6

P / E (ttm)

5.7%

ROE

$13.3B

Market cap

12.9%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Biomarin Pharmaceutical Inc earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 12.5, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

5.4%

FY2025

Return on invested capital. Return on invested capital is 5.4% in the latest fiscal year and rising from 3% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

+1.5%/yr

FY2022–FY2025

Share-count dilution. Diluted share count changed +4% over the last 3 years to FY2025 (+1.5%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.5% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~4%.

stopped

FY2020→FY2022

Shareholder returns — halted. Capital returns have STOPPED — $50M of buybacks + dividends in FY2020, but ~$0 in FY2022. A halt usually means the company is conserving cash.

Key fundamentals

Latest Revenue$3.22B

Revenue Growth YoY+12.9%

Revenue CAGR (3yr)+15.4%

Net Margin10.8%

Free Cash Flow$725.0M

Return on Equity5.7%

Debt / Equity0.21x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Biomarin Pharmaceutical Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.